Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

Clinical trial NCT04493138 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04493138
Sponsor: M.D. Anderson Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Chronic Myelomonocytic Leukemia Myelodysplastic Syndrome Myeloproliferative Neoplasm Recurrent Chronic Myelomonocytic Leukemia Recurrent Myelodysplastic Syndrome Recurrent Myeloproliferative Neoplasm

Start date: 2020-07-21
Primary completion: 2027-12-31
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.